Rhythm Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RYTM research report →
About the company
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R).
- CEO
- David Meeker
- IPO
- 2017
- Employees
- 414
- HQ
- Boston, MA, US
Price Chart
Get TickerSpark's AI analysis on RYTM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $7.31B
- P/E
- -34.06
- P/S
- 33.67
- P/B
- 58.96
- EV/EBITDA
- -41.37
- Div Yield
- 0.00%
- Gross Margin
- 89.41%
- Op Margin
- -90.89%
- Net Margin
- -93.33%
- ROE
- -203.25%
- ROIC
- -56.40%
- Revenue
- $189.76M · 45.83%
- Net Income
- $-196,539,000 · 24.58%
- EPS
- $-3.11 · 28.34%
- Op Income
- $-192,016,000
- FCF YoY
- -2.41%
- 52W High
- $122.20
- 52W Low
- $74.50
- 50D MA
- $97.41
- 200D MA
- $98.78
- Beta
- 1.88
- Avg Volume
- 804.85K
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Garfield Alastair | other | 4,445 |
| Jul 1, 26 | Garfield Alastair | other | 2,150 |
| Jul 1, 26 | Garfield Alastair | other | 4,445 |
| Jun 23, 26 | JEAN CHRISTOPHE | other | 4,712 |
| Jun 24, 26 | JEAN CHRISTOPHE | other | 3,691 |
| Jun 24, 26 | JEAN CHRISTOPHE | other | 2,324 |
| Jun 23, 26 | JEAN CHRISTOPHE | other | 4,712 |
| Jun 23, 26 | MCGIRR DAVID W J | other | 4,712 |
| Jun 24, 26 | MCGIRR DAVID W J | other | 3,691 |
| Jun 24, 26 | MCGIRR DAVID W J | other | 2,324 |
Our RYTM coverage
Recent articles, reports, and earnings notes.
Want a deeper read on RYTM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
globenewswire.com · Jul 16
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
globenewswire.com · Jul 16
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
globenewswire.com · Jul 8
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript
seekingalpha.com · Jun 17
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
proactiveinvestors.com · Jun 16
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
globenewswire.com · Jun 15
Why Is Rhythm Pharma Stock Jumping Today?
benzinga.com · Jun 15
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
globenewswire.com · Jun 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Community Sentiment
Be the first to call it — is RYTM a buy or a sell from here?